Clinicopathological Role of Serum-Derived Hyaluronan-Associated Protein (SHAP)-Hyaluronan Complex in Endometrial Cancer
2011

Role of SHAP-HA Complex in Endometrial Cancer

Sample size: 50 publication Evidence: moderate

Author Information

Author(s): Yabushita Hiromitsu, Iwasaki Keita, Kanyama Kouhei, Obayashi Yukihiko, Zhuo Lisheng, Itano Naoki, Kimata Koji, Wakatsuki Akihiko

Primary Institution: Aichi Medical University

Hypothesis

The study investigates the relationship between serum-derived hyaluronan-associated protein (SHAP)-hyaluronan complex and endometrial cancer outcomes.

Conclusion

The SHAP-HA complex is a useful marker to predict disease recurrence in endometrial cancer patients.

Supporting Evidence

  • Serum levels of SHAP-HA complex were higher in endometrial cancer patients compared to healthy controls.
  • Patients with elevated SHAP-HA complex had shorter disease-free survival.
  • SHAP-HA complex levels correlated with MMP-9 and TIMP-1 levels.

Takeaway

This study found that a protein complex in the blood can help doctors predict if endometrial cancer will come back after treatment.

Methodology

The study analyzed serum and tissue samples from 50 patients with endometrioid adenocarcinoma and measured levels of SHAP-HA complex, HA, MMP-9, and TIMP-1.

Limitations

The study only included patients diagnosed at stage I and may not be generalizable to all endometrial cancer stages.

Participant Demographics

Mean age of endometrial cancer patients was 57.24 years, and healthy controls were 54.52 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1155/2011/739150

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication